• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Access to high-tech health care. Ethics.

作者信息

Merrill J M

机构信息

Department of Medicine, Northwestern University Medical School, Chicago, IL.

出版信息

Cancer. 1991 Mar 15;67(6 Suppl):1750-2. doi: 10.1002/cncr.2820671810.

DOI:10.1002/cncr.2820671810
PMID:2001572
Abstract

Access to health care has always been limited by personal and social economics. Poverty remains one element that correlates with poor prognosis in all varieties of cancer. Prior to becoming standard therapy, elements of high-tech health care are often widely available as research protocols, participation in which is generally available without considerations of insurance coverage or personal wealth. Any person may still volunteer participation in research protocols and thereby partake in high-tech advances even before these become standard therapy. However, recent developments in the conduct of research now may limit participation. Medicare and third party insurance payers proscribe payment for research project care and always have. Recently, more than ever before, reimbursements to physicians and health care institutions have been more closely scrutinized to reject all payment in research settings. In situations in which cost and availability of the new technology, whether machine or drug, limit participation, research entrepreneurs have made research participation available to only those who can pay for it. These and similar developments threaten to limit access to high-tech health care and to actually impede cancer research.

摘要

相似文献

1
Access to high-tech health care. Ethics.
Cancer. 1991 Mar 15;67(6 Suppl):1750-2. doi: 10.1002/cncr.2820671810.
2
Building a new consensus: ethical principles and policies for clinical research on HIV/AIDS.建立新的共识:关于艾滋病毒/艾滋病临床研究的伦理原则与政策
IRB. 1991 Jan-Apr;13(1-2):1-17.
3
Drug research in humans: the ethics of nonrandomized access.人体药物研究:非随机获取的伦理问题
Clin Pharm. 1989 May;8(5):366-70.
4
A reappraisal of female adolescent participation in drug clinical trials.对女性青少年参与药物临床试验情况的重新评估。
IRB. 1999 Jan-Feb;21(1):1-5.
5
Compensating injured research subjects: I. The moral argument.
Hastings Cent Rep. 1976 Dec;6(6):21-7.
6
Consumer expectations and access to health care.消费者期望与医疗保健服务可及性。
Univ PA Law Rev. 1992 May;140(5):1881-917.
7
FDA's new rule on treatment use and sale of investigational new drugs.美国食品药品监督管理局关于研究性新药治疗用途及销售的新规定。
IRB. 1987 Jul-Aug;9(4):1-4.
8
Will Clinton's plan be fair?克林顿的计划会公平吗?
New York Rev Books. 1994 Jan 13;41(1-2):20-5.
9
Innovative therapy. The responsibility of hospitals.
J Leg Med. 1984 Jun;5(2):219-51. doi: 10.1080/01947648409513409.
10
Medical progress and national health care.医学进步与国家医疗保健。
Philos Public Aff. 1981 Winter;10(1):65-88.

引用本文的文献

1
The ethics of uninsured participants accessing healthcare in biomedical research: A literature review.无保险参与者在生物医学研究中获得医疗保健的伦理问题:文献综述。
Clin Trials. 2018 Oct;15(5):509-521. doi: 10.1177/1740774518792277. Epub 2018 Aug 2.
2
Perspectives of Japanese oncologists on the health economics of innovative cancer treatments.日本肿瘤学家对创新癌症治疗的健康经济学观点。
Int J Clin Oncol. 2016 Aug;21(4):633-641. doi: 10.1007/s10147-015-0932-2. Epub 2015 Dec 14.
3
Comparison of characteristics between patients with H7N9 living in rural and urban areas of Zhejiang Province, China: a preliminary report.
中国浙江省农村和城市地区H7N9患者特征比较:初步报告
PLoS One. 2014 Apr 7;9(4):e93775. doi: 10.1371/journal.pone.0093775. eCollection 2014.